Low cumulative disease activity is associated with higher bone mineral density in a majority Latinx and Asian US rheumatoid arthritis cohort.


Journal

Seminars in arthritis and rheumatism
ISSN: 1532-866X
Titre abrégé: Semin Arthritis Rheum
Pays: United States
ID NLM: 1306053

Informations de publication

Date de publication:
04 2022
Historique:
received: 02 09 2021
revised: 24 11 2021
accepted: 04 01 2022
pubmed: 14 2 2022
medline: 19 3 2022
entrez: 13 2 2022
Statut: ppublish

Résumé

Prior studies have found conflicting results when evaluating the association between rheumatoid arthritis (RA) disease activity and bone mineral density (BMD). Whether or not cumulative RA disease activity is associated with BMD remains unanswered. Data were from the University of California San Francisco RA Cohort from years 2006-2018. Those with BMD measures and at least two study visits prior to BMD measure were included in the study. The association between low cumulative disease activity, as measured by DAS28ESR, with the primary outcome of femoral neck BMD was assessed using multivariable linear regression. Sensitivity analyses were performed substituting CDAI for the disease activity measure as well as total hip and lumbar spine BMD as outcomes. 161 participants with RA were studied. The cohort was 62.4 ± 10.2 years old and 88% female. Hispanic/Latino (N = 73, 45%) and Asian (N = 59, 37%) were the most common racial/ethnic groups in our cohort. Mean RA duration was 10.5 ± 7.3 years and 83% were ACPA positive. Low disease activity was independently associated with higher femoral neck BMD compared to the moderate/high disease activity group (β= 0.071 [95%CI: 0.021 to 0.122], p = 0.020). The relationship between low cumulative disease activity was similar when CDAI and other BMD sites were substituted in the multivariable models. Low cumulative disease activity as measured by DAS28ESR was associated with higher femoral neck BMD, independent of traditional osteoporosis risk factors (e.g., age, sex, BMI) in a unique RA cohort. Results were similar when evaluating cumulative low CDAI and other BMD sites.

Identifiants

pubmed: 35152085
pii: S0049-0172(22)00023-3
doi: 10.1016/j.semarthrit.2022.151972
pmc: PMC8963706
mid: NIHMS1788950
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

151972

Subventions

Organisme : NIA NIH HHS
ID : K23 AG058756
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Published by Elsevier Inc.

Références

Arthritis Rheum. 2001 Jun;44(6):1254-60
pubmed: 11407683
Bone Rep. 2020 May 22;12:100284
pubmed: 32509932
Osteoporos Int. 2013 Apr;24(4):1429-36
pubmed: 23011680
Rheumatology (Oxford). 2014 Oct;53(10):1759-66
pubmed: 24764264
Clin Rheumatol. 2018 Oct;37(10):2603-2610
pubmed: 30039267
Arthritis Care Res (Hoboken). 2018 Jul;70(7):961-969
pubmed: 29106028
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Ann Rheum Dis. 2004 Dec;63(12):1576-80
pubmed: 15547081
Clin Rheumatol. 2002 May;21(2):150-8
pubmed: 12086167
Scand J Rheumatol. 2008 Jul-Aug;37(4):248-54
pubmed: 18612924
Arthritis Rheumatol. 2015 Jun;67(6):1449-55
pubmed: 25776112
Osteoporos Sarcopenia. 2020 Jun;6(2):75-81
pubmed: 32715098
Ther Adv Chronic Dis. 2020 Dec 23;11:2040622320981517
pubmed: 33489063
Arthritis Rheum. 2000 Mar;43(3):522-30
pubmed: 10728744
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
Rheumatology (Oxford). 2013 Mar;52(3):547-53
pubmed: 23221326
BMC Musculoskelet Disord. 2014 Sep 02;15:289
pubmed: 25182527
Arthritis Rheum. 2006 Oct;54(10):3104-12
pubmed: 17009229
Pharmacoeconomics. 2016 Jan;34(1):13-22
pubmed: 26643402
Arthritis Care Res (Hoboken). 2019 Dec;71(12):1540-1555
pubmed: 31709779
RMD Open. 2020 Feb;6(1):
pubmed: 32519976
Arthritis Rheumatol. 2021 Jul;73(7):1108-1123
pubmed: 34101376
Lancet. 1994 Jul 2;344(8914):23-7
pubmed: 7912297
J Bone Miner Metab. 2017 Jan;35(1):52-57
pubmed: 26369319
Ann Rheum Dis. 2009 Mar;68(3):373-6
pubmed: 18408246
J Rheumatol. 2000 Nov;27(11):2582-9
pubmed: 11093437
Osteoporos Int. 2008 Apr;19(4):385-97
pubmed: 18292978

Auteurs

Katherine D Wysham (KD)

Arthritis Section, VA Puget Sound Health Care System, Seattle, WA, USA; Division of Rheumatology, Department of Medicine, University of Washington Department of Medicine, Seattle, WA, USA. Electronic address: kwysham@uw.edu.

Jane Shofer (J)

Arthritis Section, VA Puget Sound Health Care System, Seattle, WA, USA; Division of Rheumatology, Department of Medicine, University of Washington Department of Medicine, Seattle, WA, USA.

Gabriella Lui (G)

Division of Rheumatology, Department of Medicine, University of Washington Department of Medicine, Seattle, WA, USA.

Laura Trupin (L)

Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.

James S Andrews (JS)

Division of Rheumatology, Department of Medicine, University of Washington Department of Medicine, Seattle, WA, USA.

Dennis M Black (DM)

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.

Jonathan Graf (J)

Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.

Dolores M Shoback (DM)

Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Endocrinology Section, San Francisco VA Medical Center, San Francisco, CA, USA.

Patricia P Katz (PP)

Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH